Key facts
- It has raised $400K; the latest was Early Stage VC ($400K) in Dec 2025.
- Notable investors include Innovatiefonds Noord-Holland, Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Juvant Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Juvant Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Juvant Medical
Developer of surgical oncology equipment designed to distinguish healthy and tumorous tissue in real time using diffuse reflectance spectroscopy. The company offers intraoperative tissue-differentiation technology that guides surgeons during tumor removal, enabling surgical teams to achieve cleaner margins and reduce the need for post-operative treatments.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2025
- Ownership
- Privately Held (backing)
Juvant Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Juvant Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Juvant Medical in its N-PORT filings yet. We sweep new filings monthly.